Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754492 · ClinicalTrials.gov registry record · NA
Evaluation of Trima Version 7.0 Platelets in 100% Plasma
A NA study, sponsored by Terumo BCT.
- Completed
- Registry status
- NA
- Development phase
- 334
- Enrollment target
NCT02754492 is a NA study that has completed, run by Terumo BCT. The registered enrollment target is 334 participants.
The verdict
NCT02754492, a NA study, has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- NA
- Development phase
- 334 participants
- Enrollment target
Study Summary
To verify that platelets collected on the Trima Accel system with Version 7.0 software enhancements and stored in 100% plasma meet the FDA requirements for leukoreduction (\< 5.0 × 10\^6 residual white blood cells \[WBC\] per transfusable unit).
Interventions
- DEVICE Trima Accel System with Version 7.0 Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-02-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02754492
The ClinicalTrials.gov registry entry for NCT02754492 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Terumo BCT, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trima Accel System with Version 7.0 Software is the first listed.
NCT02754492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02754492 about?
NCT02754492 is a clinical study titled "Evaluation of Trima Version 7.0 Platelets in 100% Plasma". To verify that platelets collected on the Trima Accel system with Version 7.0 software enhancements and stored in 100% plasma meet the FDA requirements for leukoreduction (\< 5.0 × 10\^6 residual white blood cells \[WBC\] per transfusable unit).
What is the current status of trial NCT02754492?
This trial is currently completed. It is a NA study. The enrollment target is 334 participants. The study started on 2016-04. Estimated completion is 2017-02-15.
What interventions are being tested in trial NCT02754492?
The interventions under investigation include: Trima Accel System with Version 7.0 Software (DEVICE).
Who is sponsoring clinical trial NCT02754492?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.